Ignite Creation Date:
2024-05-05 @ 9:46 PM
Last Modification Date:
2024-10-26 @ 10:09 AM
Study NCT ID:
NCT00965718
Status:
COMPLETED
Last Update Posted:
2023-07-19
First Post:
2009-08-24
Brief Title:
Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
Sponsor:
GC Cell Corporation
Organization:
GC Cell Corporation
Study Overview
Official Title:
Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of Activated T-lymphocyte Immuncell-LC Cell Therapy in Gemcitabine Refractory Advanced Pancreatic Cancer
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase 2 Clinical trial to Evaluate the efficacy and safety of activated T-lymphocyte Immuncell-LC cell therapy in Gemcitabine refractory advanced pancreatic cancer
Detailed Description:
This was designed as a single-center single group clinical trial and subjects include patients with pathologically-confirmed Gemcitabine refractory advanced pancreatic cancer
If subjects agree to participate in the clinical trial by signing a written consent only appropriate subjects who meet the criteria on the examinations and tests will undergo this clinical trial To participate in the clinical trial subjects blood of more than 60 ml should be withdrawn to make a study drug at least 2 weeks before administration Subjects should visit to hospital according to the protocol and receive a study drug Therapeutic response rate overall survival rate time to progression and the quality of life should be investigated
If subjects agree to participate in the clinical trial by signing a written consent only appropriate subjects who meet the criteria on the examinations and tests will undergo this clinical trial To participate in the clinical trial subjects blood of more than 60 ml should be withdrawn to make a study drug at least 2 weeks before administration Subjects should visit to hospital according to the protocol and receive a study drug Therapeutic response rate overall survival rate time to progression and the quality of life should be investigated
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None